Merus results, update

 Petosemtamab in combination with Keytruda 1L initial interim clinical data planned for 1H24; 2L+ HNSCC monotherapy clinical update planned 2024

– Zeno interim clinical data continue to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions

– Based on the Company’s current operating plan and recent oversubscribed public offering raising approximately $172M gross proceeds, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027

https://www.globenewswire.com/news-release/2023/11/02/2772843/37568/en/Merus-Announces-Financial-Results-for-the-Third-Quarter-2023-and-Provides-Business-Update.html